NASDAQ:APM

Aptorum Group (APM) Stock Forecast, Price & News

$2.25

+0.15 (+7.14%)

(As of 02:15 PM ET)

Compare

Today's Range: $2.20
▼
$2.29
50-Day Range: $1.76
▼
$2.75
52-Week Range: $1.72
▼
$13.00

Volume: 4,239 shs
Average Volume: 165,938 shs
Market Capitalization: $8.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $80.00

Aptorum Group MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 3,455.6% Upside
$80.00 Price Target
Short Interest: Healthy
2.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.89
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Aptorum Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $80.00, Aptorum Group has a forecasted upside of 3,455.6% from its current price of $2.25.
Amount of Analyst Coverage
Aptorum Group has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.25% of the float of Aptorum Group has been sold short.
Short Interest Ratio / Days to Cover
Aptorum Group has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aptorum Group has recently decreased by 66.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aptorum Group does not currently pay a dividend.
Dividend Growth
Aptorum Group does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APM.

3.8

News and Social Media Coverage

News Sentiment
Aptorum Group has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aptorum Group this week, compared to 0 articles on an average week.
MarketBeat Follows
4 people have added Aptorum Group to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aptorum Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
63.99% of the stock of Aptorum Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.89% of the stock of Aptorum Group is held by institutions.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Aptorum Group has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aptorum Group (NASDAQ:APM) Stock

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

APM Price History

30 days | 90 days | 365 days | Advanced Chart

APM Stock News Headlines

September 14, 2023 | benzinga.com

Autism Summit Garners Over 30,000 Attendees: APM Announces Date of its Upcoming Conference

August 8, 2023 | finance.yahoo.com

APM - Aptorum Group Limited

September 27, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

June 27, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

June 22, 2023 | finance.yahoo.com

Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma

June 9, 2023 | finance.yahoo.com

Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris

May 26, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency

May 5, 2023 | finance.yahoo.com

Aptorum Group Receives Nasdaq Notification of Minimum Stockholders’ Equity Deficiency

September 27, 2023 | Behind the Markets (Ad)

66,000% upside on tiny biotech?

The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.

May 4, 2023 | msn.com

Why Arconic Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket

May 1, 2023 | finance.yahoo.com

Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group’s Subsidiary Paths Innovations Limited

May 1, 2023 | finance.yahoo.com

Aptorum Group Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

April 28, 2023 | finance.yahoo.com

Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update

April 25, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Announces Completion of $3 Million Convertible Note due 2023

April 25, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Announces 1-for-10 Reverse Stock Split

March 29, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Launches NativusWell, a Novel Nutraceutical for Menopause, in China

March 27, 2023 | nasdaq.com

Aptorum Group Inks Non-binding LoI And Term Sheet To Buy 100% Of URF Holding Group

March 27, 2023 | finance.yahoo.com

Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group

March 17, 2023 | finanznachrichten.de

Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report

March 2, 2023 | finance.yahoo.com

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in China

February 25, 2023 | finanznachrichten.de

Aptorum Group Limited: Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

February 10, 2023 | finance.yahoo.com

Aptorum Group Regains Compliance with Nasdaq Minimum Bid Price and Receives Nasdaq Notification of Minimum Market Value of Publicly Held Shares Deficiency

February 6, 2023 | finance.yahoo.com

Aptorum Group Limited to Hold Special Extraordinary Meeting of Shareholders on February 21, 2023

January 23, 2023 | finance.yahoo.com

Owning 74% in Aptorum Group Limited (NASDAQ:APM) means that insiders are heavily invested in the company's future

January 20, 2023 | msn.com

Aptorum Group climbs 3%, announces 1-for-10 reverse stock split

January 20, 2023 | finance.yahoo.com

Aptorum Group Announces 1-for-10 Reverse Stock Split

January 4, 2023 | finance.yahoo.com

Aptorum Group Announces Publication of a Co-authored Paper on its PathsDx Technology - a Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow for Liquid Biopsy based Diagnosis of Infectious Diseases on Illumina Platforms

See More Headlines

Receive APM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptorum Group and its competitors with MarketBeat's FREE daily newsletter.

APM Company Calendar

Today: 9/27/2023
Next Earnings (Estimated): 9/30/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APM
CUSIP: N/A
CIK: 1734005
Web: www.aptorumgroup.com
Phone: 442080929299
Fax: N/A
Employees: 18
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $80.00
High Stock Price Forecast: $80.00
Low Stock Price Forecast: $80.00
Forecasted Upside/Downside: +3,455.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 0.57
Quick Ratio: 0.56

Sales & Book Value

Annual Sales: $1.30 million
Price / Sales: 6.18
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.19 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 3,570,000
Free Float: 1,286,000
Market Cap: $8.03 million
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Darren Lui (Age 41)
CEO, Chief Accounting Officer & Exec. Director
Comp: $420.72k

Mr. Martin Siu (Age 44)
Head of Fin.
Comp: $87.34k

Dr. Clark Cheng (Age 42)
Chief Medical Officer & Exec. Director
Comp: $637.75k

Key Competitors

View All Competitors

APM Stock - Frequently Asked Questions

Should I buy or sell Aptorum Group stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptorum Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APM shares.
View APM analyst ratings or view top-rated stocks.
What is Aptorum Group's stock price forecast for 2023?: 1 equities research analysts have issued 12 month price objectives for Aptorum Group's shares. Their APM share price forecasts range from $80.00 to $80.00. On average, they predict the company's stock price to reach $80.00 in the next year. This suggests a possible upside of 3,455.6% from the stock's current price.
View analysts price targets for APM or view top-rated stocks among Wall Street analysts.
How have APM shares performed in 2023?: Aptorum Group's stock was trading at $5.5010 on January 1st, 2023. Since then, APM stock has decreased by 59.1% and is now trading at $2.25.
View the best growth stocks for 2023 here.
Are investors shorting Aptorum Group?: Aptorum Group saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 29,300 shares, a drop of 66.7% from the August 31st total of 88,000 shares. Based on an average daily volume of 150,200 shares, the short-interest ratio is currently 0.2 days. Currently, 2.3% of the shares of the company are sold short.
View Aptorum Group's Short Interest.
When is Aptorum Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Saturday, September 30th 2023.
View our APM earnings forecast.
When did Aptorum Group's stock split?: Shares of Aptorum Group reverse split on Monday, January 23rd 2023. The 1-10 reverse split was announced on Monday, January 23rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Aptorum Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aptorum Group investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Cidara Therapeutics (CDTX), Quest Diagnostics (DGX), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Aridis Pharmaceuticals (ARDS).
What is Aptorum Group's stock symbol?: Aptorum Group trades on the NASDAQ under the ticker symbol "APM."
How do I buy shares of Aptorum Group?: Shares of APM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aptorum Group's stock price today?: One share of APM stock can currently be purchased for approximately $2.25.
How much money does Aptorum Group make?: Aptorum Group (NASDAQ:APM) has a market capitalization of $8.03 million and generates $1.30 million in revenue each year.
How can I contact Aptorum Group?: Aptorum Group's mailing address is 17/F GUANGDONG INVESTMENT TOWER 148 CONNAUGHT ROAD CENTRAL, HONG KONG K3, 999077. The official website for the company is www.aptorumgroup.com. The company can be reached via phone at 442080929299 or via email at investor.relations@aptorumgroup.com.

This page (NASDAQ:APM) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial